Suppression by pravastatin, an inhibitor of p21(ras) isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats

British Journal of Cancer

Volumn 77, Issue 4, 1998, Pages 581-587

  Tatsuta, M ^a   Iishi, H ^a   Baba, M ^a   Iseki, K ^a   Yano, H ^a   Uehara, H ^a   Yamamoto, R ^a   Nakaizumi, A ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Hepatocarcinogenesis; N nitrosomorpholine; P21(ras) isoprenylation; Pravastatin

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE; MEMBRANE PROTEIN; NITROSOMORPHOLINE; PRAVASTATIN; PROTEIN P21; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; HISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; ISOPRENYLATION; LABELING INDEX; LIVER CARCINOGENESIS; LIVER INJURY; LIVER NODULE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031985149     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.94     Document Type: Article

References (34)

1. Baba M, Yamamoto R, Iishi H and Tatsuta M (1997) Analysis of Ha-ras gene mutation of hepatic lesions induced by N-nitrosomorpholine and inhibition of hepatocarcinogenesis in Sprague-Dawley rats by mutated Ha-ras antisense. Int J Cancer 72: 815-820
2. Buchwald H (1992) Cholesterol inhibition, cancer and chemotherapy. Lancet 339: 1154-1156
3. Cox AD and Der CJ (1992) Protein prenylation: more than just glue? Curr Opin Cell Biol 4: 1008-1016
4. ras but does not affect their function or localization. Cancer Res 55: 3295-3304
5. De Clue JE, Vass WC, Papageorge AG, Lowy DR and Willumsen BM (1991) Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51: 712-717
6. Egan SE and Weinberg RA (1993) The pathway to signal achievement. Nature 365: 781-783
7. Fairbanks KP, Witte LD and Goodman DS (1981) Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J Biol Chem 259: 1546-1551
8. Goldstein JL, Helgeson JAS and Brown MS (1979) Inhibition of cholesterol synthesis with compactin renders growth of cultured cell dependent on the low density lipoprotein receptors. J Biol Chem 254: 5403-5409
9. Grand RJA and Owen D (1991) The biochemistry of ras p21. Biochem J 279: 609-631
10. Gratzner HG (1982) Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 218: 474-475
11. Gu JR, Hu LF, Cheng YC and Wan DF (1986) Oncogenes in human primary hepatic cancer. J Cell Physiol 4 (Suppl): 13-20
12. Habenicht AJR, Glomset JA and Ross R (1980) Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 255: 5134-5140
13. Herold G, Jungwirth R, Rogler G, Geerling I and Stange EF (1995) Influence of cholesterol supply on cell growth and differentiation in cultured enterocytes (CoCa-2). Digestion 56: 57-66
14. Institute of Laboratory Animal Resources (1980) Histologic typing of liver tumors of the rats. J Natl Cancer Inst 64: 177-207
15. Kawata S, Kakimoto H, Ishiguro H, Yamasaki E, Inui Y and Matsuzawa Y (1992) Effect of pravastatin, a potent 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on survival of AH 130 hepatoma-bearing rats. Jpn J Cancer Res 83: 1120-1123
16. Kawata S, Nagase T, Yamasaki E, Ishiguro H and Matsuzawa Y (1994) Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer 69: 1015-1020
17. Lowry DR and Willumsen BM (1993) Function and regulation of ras. Annu Rev Biochem 62: 851-891
18. Maltese WA (1984) Induction of differentiation in murine neuroblastoma cells by mevinolin, a competitive inhibitor of 3-hydroxyl-3-methylglutaryl coenzyme A reductase. Biochem Biophys Res Commun 120: 454-460
19. Maltese WA, Defendini R, Green RA, Sheridan KM and Donley DK (1985) Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Clin Invest 76: 1748-1754
20. McCormick F (1993) How receptors turn RAS on. Nature 363: 15-16
21. Miller RG Jr (1966) Simultaneous Statistical Inference. McGraw-Hill: New York
22. Morris TJ, Palm SL, Furcht LL and Buchwald H (1995) Effect of lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth. Ann Surg Oncol 2: 266-274
23. Morstyn G, Hsu SM, Kinsella T, Gratzner H, Russo A and Mitchell JB (1983) Bromodeoxyuridine in tumors and chromosomes detected with monoclonal antibody. J Clin Invest 72: 1844-1850
24. Narisawa T, Fukaura Y, Terada K, Umezawa A, Tanida N, Yazawa K and Ishikawa C (1994) Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 15: 2045-2048
25. Robinson RL, Suter W and Cox RH (1994) Carcinogenicity and mutagenicity studies with fluvastatin, a new, entirely synthetic HMG-CoA reductase inhibitor. Fundam Appl Toxicol 23: 9-20
26. Ruttenberg AH, Kim H, Fuckbein JW, Hanker JS, Wasseskrung HL and Seligma AM (1969) Histochemical and ultrastructural demonstration of gamma-glutamyl transpeptidase activity. J Histochem Cytochem 17: 517-526
27. Schmitz GG, Walter T, Seibl R and Kessler C (1991) Nonradioactive labeling of oligonucleotides in vitro with the hapten digoxigenin by tailing with terminal transferase. Anal Biochem 192: 222-231
28. Siegel S (1956) Nonparametric Statistic for the Behavioral Sciences. McGraw-Hill: New York
29. Sinensky M, Back LA, Leonard S and Evans R (1990) Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 265: 19937-19941
30. Snedecor GW and Cochran WG (1967) Statistical Methods. Iowa University Press: Ames, IA
31. Sternberg LA, Hardy PH, Cuculis JJ and Mayer HG (1970) The unlabeled antibody enzyme method of immunochemistry. Preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochaetes. J Histochem Cytochem 8: 315-333
32. Sumi S, Beauchamp RD, Townsend CM, Jr, Pour PM, Ishizuka J and Thompson JC (1991) Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas 9: 657-717
33. Sumi S, Beauchamp RD, Townsend CM, Jr, Uchida T, Murakami M, Rajaraman S, Ishizuka J and Thompson JC (1992) Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 103: 982-989
34. Ura H, Obara T, Nishino N, Tanno S, Okamura K and Namiki M (1994) Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene. Jpn J Cancer Res 85: 633-638